A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening
(2006) In International Journal of Cancer 118(4). p.791-796- Abstract
- Cervical cancer remains a significant public health concern, both at a global and a European level. A number of new technologies such as diagnostic tests for human papillomavirus (HPV) have a potential to assist with the reduction of this disease. However, both the efficacy and the cost-effectiveness of these new technologies must be established in properly designed trials before they can be implemented within national public health programs. Our study reviews the randomized controlled trials that are currently being conducted in Europe to establish the performance of HPV testing as a primary cervical cancer screening test. (c) 2005 Wiley-Liss, Inc.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/419449
- author
- Davies, P ; Arbyn, M ; Dillner, Joakim LU ; Kitchener, HC ; Meijer, CJLM ; Ronco, G and Hakama, M
- organization
- publishing date
- 2006
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- review, trial, randomized controlled, screening, human papillomavirus, cervical cancer
- in
- International Journal of Cancer
- volume
- 118
- issue
- 4
- pages
- 791 - 796
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:16287075
- wos:000234944000001
- scopus:31544466266
- pmid:16287075
- ISSN
- 0020-7136
- DOI
- 10.1002/ijc.21611
- language
- English
- LU publication?
- yes
- id
- 998d019e-7611-4e59-ad7f-8c09169b0f3a (old id 419449)
- date added to LUP
- 2016-04-01 12:09:33
- date last changed
- 2022-02-26 02:41:01
@article{998d019e-7611-4e59-ad7f-8c09169b0f3a, abstract = {{Cervical cancer remains a significant public health concern, both at a global and a European level. A number of new technologies such as diagnostic tests for human papillomavirus (HPV) have a potential to assist with the reduction of this disease. However, both the efficacy and the cost-effectiveness of these new technologies must be established in properly designed trials before they can be implemented within national public health programs. Our study reviews the randomized controlled trials that are currently being conducted in Europe to establish the performance of HPV testing as a primary cervical cancer screening test. (c) 2005 Wiley-Liss, Inc.}}, author = {{Davies, P and Arbyn, M and Dillner, Joakim and Kitchener, HC and Meijer, CJLM and Ronco, G and Hakama, M}}, issn = {{0020-7136}}, keywords = {{review; trial; randomized controlled; screening; human papillomavirus; cervical cancer}}, language = {{eng}}, number = {{4}}, pages = {{791--796}}, publisher = {{John Wiley & Sons Inc.}}, series = {{International Journal of Cancer}}, title = {{A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening}}, url = {{http://dx.doi.org/10.1002/ijc.21611}}, doi = {{10.1002/ijc.21611}}, volume = {{118}}, year = {{2006}}, }